ASHBURN, Virginia — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to QRX003 for the treatment of Peeling Skin Syndrome (PSS). QRX003...

WALTHAM, Mass. — Pretzel Therapeutics, Inc., a clinical-stage biotechnology company advancing a new class of medicines designed to restore mitochondrial function, improve cellular energetics and impede disease progression across a range of neurological and rare diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation...

KING OF PRUSSIA, Pa. — Aclipse Therapeutics (“Aclipse”), a clinical-stage biopharmaceutical company developing best-in-class therapies for chronic, rare, and severe diseases, today announced an agreement that provides Aclipse the option to acquire Cypress BioPharma (“Cypress”), a developer of novel therapies for rare kidney diseases. Upon completion, the transaction would establish...